Project Grant R37CA296416
Award Date 9/9/25
Completion Date 8/31/30
Dollars Obligated $513K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $931,113 project grant to The University of Texas MD Anderson Cancer Center, with a performance period from November 1, 2024 to October 31, 2027. The grant supports research targeting RNA surveillance machinery in neurofibromatosis type 1 (NF1)-mutant malignant peripheral nerve sheath tumors (MPNSTs). As a leading academic cancer research institution, MD Anderson has extensive expertise...
- The Department of the Army Medical Command awarded a $580,444 Project Grant to The University of Texas M.D. Anderson Cancer Center through the Military Medical Research and Development program. The grant will fund research from August 15, 2022 to August 14, 2025 to target STAT3 signaling pathways to promote recovery from neuropathic pain. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of improving military and public...
- This federal Project Grant award of $1,348,314.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center. The funding supports a research project titled "BUILDING T-CELL PRODUCTS IN NF1-ASSOCIATED MPNST THROUGH ANTIGEN DISCOVERY AND EPIGENOME TARGETING". The project aims to conduct advanced biomedical research to transform healthcare for military service members,...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $816,554 to The University of Texas M.D. Anderson Cancer Center to develop and validate a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) associated with colorectal cancer and oxaliplatin treatment. The project aims to establish the face, construct, and predictive validity of this refined mouse...
- This Project Grant award of $489,767.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to develop T-cell products for the treatment of Neurofibromatosis Type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNSTs). The research aims to identify relevant tumor antigens and target the epigenome to enhance T-cell-mediated therapies for this rare and...
- The University of Texas MD Anderson Cancer Center received a $1,431,215 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop T-cell products for the treatment of NF1-associated malignant peripheral nerve sheath tumors (MPNST). The project aims to discover new antigens and leverage epigenome targeting to engineer improved T-cell therapies for this rare and aggressive cancer. The award commenced on October 1, 2025, with a...
- The University of Texas MD Anderson Cancer Center received a $1,041,605 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research titled "INTERROGATING TUMOR-IMMUNE-NEURON CROSS TALK AT SINGLE-CELL RESOLUTION IN A PANEL OF NOVEL SOMATIC TRANSGENIC NF1 TUMOR MODELS". This 3-year award, starting on September 1, 2023, will support basic and translational cancer research focused on understanding the interactions...
- The University of Texas MD Anderson Cancer Center (MD Anderson) has been awarded a $1,457,978 Project Grant under the Military Medical Research and Development program (CFDA 12.420), funded by the Defense Health Agency. This grant will support MD Anderson's research project titled "Cortical and Amygdala Circuit Mechanisms for Chronic Pain" over the period of August 1, 2024 to July 31, 2028. As a leading cancer research and treatment center, MD Anderson has a track record of...
- This $391,325 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of non-invasive, quantitative microscopic biomarkers to assess chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients. The principal investigator, Dr. Kang from the University of Arizona, is leading the effort to utilize portable confocal microscopy (PCM) technology to visualize changes in Meissner's corpuscles, which are nerve...
- The National Cancer Institute (NCI) awarded a $179,403 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the University of Nebraska Medical Center (UNMC) to develop and screen novel flupirtine analogue compounds as non-opioid analgesics for treating chemotherapy-induced neuropathic pain (CINP). The 2-year project aims to synthesize and evaluate flupirtine analogues that can effectively relieve CINP while mitigating the liver toxicity concerns associated with the parent...